Document Detail

Safety of oral terbinafine for toenail onychomycosis.
MedLine Citation:
PMID:  9425805     Owner:  NLM     Status:  MEDLINE    
This open-label multicenter study evaluated the safety and efficacy of 12, 18, and 24 weeks of daily treatment with a 250-mg tablet of terbinafine for onychomycosis of the toenails. The safety data for 1,508 patients with a mean age of 50 years are reported here. Percentages below are based on this denominator. All patients received at least 12 weeks of therapy, with a possible addition of 6 or 12 weeks depending on disease extent. Patients were evaluated at baseline and at weeks 6, 12, 24, 30, 36, 48, and 72. Adverse events were reported in 674 (44.7%) patients; the events were considered unrelated to terbinafine in 557 (36.9%) patients and causally related or of uncertain relationship to terbinafine in 117 (7.8%) patients. Most events involved the skin, the gastrointestinal system, or the respiratory system. Statistically similar results were found for the elderly (over 60 years) and diabetic subpopulations. The study results confirm the safety of terbinafine in the population at large and show no differences for either the elderly or diabetic patients, who are at increased risk for onychomycosis and who frequently take concomitant medications with potential for drug interactions.
R Pollak; S A Billstein
Related Documents :
902055 - Arterial embolism in thyrotoxicosis with atrial fibrillation.
6847805 - Effects of abrupt changes in cycle length on refractoriness of the his-purkinje system ...
1617825 - Direct current cardioversion of established atrial fibrillation.
9425805 - Safety of oral terbinafine for toenail onychomycosis.
2955675 - Evaluation of the calcium-antagonist nimodipine for the prevention of vasospasm after a...
22247355 - Prevalence of monoclonal gammopathy among patients with psoriatic arthritis.
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  Journal of the American Podiatric Medical Association     Volume:  87     ISSN:  8750-7315     ISO Abbreviation:  J Am Podiatr Med Assoc     Publication Date:  1997 Dec 
Date Detail:
Created Date:  1998-02-05     Completed Date:  1998-02-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8501423     Medline TA:  J Am Podiatr Med Assoc     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  565-70     Citation Subset:  IM    
Medical Affairs, Novartis Pharmaceuticals Corp, East Hanover, NJ, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antifungal Agents / therapeutic use*
Foot Dermatoses / drug therapy
Naphthalenes / therapeutic use*
Onychomycosis / drug therapy*
Reg. No./Substance:
0/Antifungal Agents; 0/Naphthalenes; 91161-71-6/terbinafine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Traditional approaches to treatment of onychomycosis.
Next Document:  1997 Diabetes Survey. Statistical results. Al Fisher Associates, Inc.